191851-84-0

Upstream product

• 191851-83-9 C₁₈H₂₃NO₆ 

Downstream Products

• 317357-80-5 methyl 4-[(3R,4S)-isopropylidenedioxy-1-[4-[N-(2-methylphenyl)ureido]-3-methoxyphenylacetyl]-(2R)-pyrrolidinyl]methoxybenzoate 
• 317357-81-6 methyl 4-[(3R,4S)-dihydroxy-1-[4-[N-(2-methylphenyl)ureido]-3-methoxyphenylacetyl]-(2R)-pyrrolidinyl]methoxybenzoate 
• 317357-78-1 methyl 4-[1-benzyloxycarbonyl-(3R,4S)-isopropylidenedioxy-(2R)-pyrrolidinyl]methoxybenzoate 
• 317357-79-2 methyl 4-[(3R,4S)-isopropylidenedioxy-(2R)-pyrrolidinyl]methoxybenzoate 
• 111265-96-4 (2R,3R,4S)-1-(benzyloxycarbonyl)-2-(hydroxymethyl)pyrrolidine-3,4-diol 3,4-O-isopropylidene acetal 

Relevant academic research and scientific papers

HIV protease inhibitors

Combinatorial libraries of HIV and FIV protease inhibitors are characterized by alpha-keto amide or hydroxyethylamine core structures flanked by on one side by substituted pyrrolidines, piperidines, or azasugars and on the other side by phenylalanine, tyrosine, or substituted tyrosines. The libraries are synthesized via a one step coupling reaction. Highly efficacious drug candidates are identified by screening the libraries for binding and inhibitory activity against both HIV and FIV protease. Drug candidates displaying clinically useful activity against both HIV and FIV protease are identified as being potentially resistive against a loss of inhibitory activity due to development of resistant strains of HIV.

VLA-4 inhibitor compounds

Compounds that selectively inhibit the binding of ligands to alpha4beta1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.